EE140 Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective
Abstract
Authors
JF Wallace N Adair JR Perez T Hall MA Bilen M Sussman